Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for AMRN
-0.02 (-1.54%)
Feb 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.25 - 1.36
52 week 1.05 - 3.33
Open 1.30
Vol / Avg. 447,371.00/1.19M
Mkt cap 220.09M
P/E     -
Div/yield     -
EPS -0.82
Shares 182.53M
Beta 1.40
Inst. own 38%
Feb 25, 2016
Q4 2015 Amarin Corporation PLC Earnings Release - Tentative - 9:30AM EST - Add to calendar
Jan 11, 2016
Preliminary Q4 2015 Amarin Corporation PLC Corporate Sales Release
Dec 9, 2015
Amarin Corporation PLC at Oppenheimer Healthcare Conference
Dec 1, 2015
Amarin Corporation PLC at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -142.79% -103.99%
Operating margin -120.16% -106.86%
EBITD margin - -175.47%
Return on average assets -65.17% -26.61%
Return on average equity - -
Employees 201 -
CDP Score - -


2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarin's lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers, as well as regional wholesalers and specialty pharmacy providers, who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.

Officers and directors

Lars G. Ekman Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 55
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Age: 52
Bio & Compensation  - Reuters
Michael J. Farrell Vice President - Finance (principal accounting officer and principal financial officer)
Age: 37
Bio & Compensation  - Reuters
Craig B. Granowitz M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 52
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Non-Executive Independent Director
Age: 50
Bio & Compensation  - Reuters
Patrick J. O'Sullivan Non-Executive Independent Director
Age: 73
Bio & Compensation  - Reuters